Mannkind Corp SEC filings MNKD

Mannkind Corp has 1,002 filings in SEC EDGAR's recent list, going back to Aug 2, 2013. Its latest annual report, Form ARS, was filed on Apr 7, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.

Mannkind Corp SEC filings
Form Description Filed Period
424B7 Filing Aug 21, 2026 —
S-3ASR Automatic shelf registration Feb 26, 2025 —
S-8 Employee stock plan registration Aug 23, 2023 —
S-3ASR Automatic shelf registration Feb 24, 2022 —
S-8 Employee stock plan registration Aug 7, 2020 —
424B5 Prospectus supplement May 7, 2019 —
S-3 Shelf registration Mar 29, 2019 —
424B5 Prospectus supplement Dec 21, 2018 —
424B5 Prospectus supplement Dec 19, 2018 —
S-8 Employee stock plan registration Aug 7, 2018 —
S-8 Employee stock plan registration Jun 5, 2018 —
424B5 Prospectus supplement Apr 6, 2018 —
424B5 Prospectus supplement Feb 28, 2018 —
424B5 Prospectus supplement Oct 11, 2017 —
S-1 Registration statement Jul 3, 2017 —
S-8 Employee stock plan registration Aug 29, 2016 —
424B5 Prospectus supplement May 10, 2016 —
424B5 Prospectus supplement May 4, 2016 —
S-3 Shelf registration Apr 18, 2016 —
424B7 Filing Dec 15, 2015 —
424B5 Prospectus supplement Nov 9, 2015 —
424B5 Prospectus supplement Sep 4, 2015 —
S-3ASR Automatic shelf registration Sep 4, 2015 —
424B5 Prospectus supplement Mar 4, 2014 —

Showing 24 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
MNKD (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Danbury, CT
SEC filer status
Large accelerated filer
SEC CIK
899460

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.